Hypoxia, a novel inducer of acute phase gene expression in a human hepatoma cell line.
Transcriptional regulation of gene expression by hypoxia is an important, but yet only marginally characterized mechanism by which organisms adapt to low oxygen concentrations. The human hepatoma cell line HepG2 is a widely used model for studying hypoxic induction of the hematopoietic growth factor erythropoietin. In an attempt to identify additional genes expressed in HepG2 cells during hypoxia, we differentially screened a cDNA library derived from hypoxic (1% O2) HepG2 cells using probes isolated from either normoxic (21% O2) or hypoxic cells. Two genes were identified, one encoding aldolase, a member of the glycolytic enzymes, and the other encoding alpha 1-antitrypsin which belongs to the family of the acute phase (AP) responsive proteins. Whereas hypoxic induction of glycolytic enzymes is well established, oxygen-dependent regulation of AP genes has not been reported so far. AP proteins are liver-derived plasma proteins whose production during inflammation is either up-regulated (positive AP reactants) or down-regulated (negative AP reactants). In the present study, we demonstrate that on the mRNA level hypoxic stimulation of HepG2 cells led to (i) an induction of the positive AP reactants alpha 1-antitrypsin, alpha 1-antichymotrypsin, complement C3, haptoglobin, and alpha 1-acid glycoprotein; (ii) a down-regulation of the negative AP reactant albumin; (iii) an up-regulation of the negative AP reactant transferrin; and (iv) unchanged levels of the positive AP reactants alpha- and beta-fibrinogen as well as hemopexin. Cycloheximide inhibited hypoxic up-regulation of AP mRNAs demonstrating that de novo protein synthesis is required for hypoxic induction. Nuclear run-on assays indicate that the hypoxic increase in AP mRNAs is mainly due to transcriptional regulation. The hypoxic response was compared to AP stimulation by interleukin 6. The results suggest that the adaptive response to hypoxia overlaps with, but is not identical with, the AP response mediated by interleukin 6.
D000209:Acute-Phase Proteins / Q000096:biosynthesis*; D000818:Animals; D001483:Base Sequence; D015152:Blotting, Northern; D006528:Carcinoma, Hepatocellular; D015687:Cell Hypoxia; D002460:Cell Line; D003513:Cycloheximide / Q000494:pharmacology; D017931:DNA Primers; D018076:DNA, Complementary; D003907:Dexamethasone / Q000494:pharmacology; D016228:Endothelial Growth Factors / Q000096:biosynthesis; D004921:Erythropoietin / Q000096:biosynthesis; D005634:Fructose-Bisphosphate Aldolase / Q000096:biosynthesis / Q000235:genetics; D015870:Gene Expression; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D015723:Gene Library; D006019:Glycolysis; D006801:Humans; D015850:Interleukin-6 / Q000494:pharmacology; D008113:Liver Neoplasms; D008222:Lymphokines / Q000096:biosynthesis; D051379:Mice; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000515:alpha 1-Antitrypsin / Q000096:biosynthesis / Q000235:genetics
D000209:Acute-Phase Proteins; D017931:DNA Primers; D018076:DNA, Complementary; D016228:Endothelial Growth Factors; D015850:Interleukin-6; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000515:alpha 1-Antitrypsin; D004921:Erythropoietin; D003907:Dexamethasone; D003513:Cycloheximide; D005634:Fructose-Bisphosphate Aldolase